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Abstract Human SH-SY5Y neuroblastoma cells maintain
their potential for differentiation and regression in culture
conditions. The induction of differentiation could serve as a
strategy to inhibit cell proliferation and tumor growth. Pre-
vious studies have shown that differentiation of SH-SY5Y
cells can be induced by all-trans-retinoic-acid (RA) and
cholesterol (CHOL). However, signaling pathways that lead
to terminal differentiation of SH-SY5Y cells are still largely
unknown. The goal of this study was to examine in the RA
and CHOL treated SH-SY5Y cells the additive impacts of
estradiol (E2) and brain-derived neurotrophic factor (BDNF)
on cell morphology, cell population growth, synaptic vesicle
recycling and presence of neurofilaments. The above fea-
tures indicate a higher level of neuronal differentiation. Our
data show that treatment for 10 days in vitro (DIV) with RA
alone or when combined with E2 (RE) or CHOL (RC), but
not when combined with BDNF (RB), significantly
(p\ 0.01) inhibited the cell population growth. Synaptic
vesicle recycling, induced by high-K? depolarization, was
significantly increased in all treatments where RA was
included (RE, RC, RB, RCB), and when all agents were
added together (RCBE). Specifically, our results show for the
first time that E2 treatment can alone increase synaptic
vesicle recycling in SH-SY5Y cells. This work contributes to
the understanding of the ways to improve suppression of
neuroblastoma cells’ population growth by inducing matu-
ration and differentiation.
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Abbreviations
AChE Acetylcholinesterase
Arc Activity-regulated cytoskeleton associated
protein
BDNF Brain-derived neurotrophic factor
CHOL Cholesterol
CO2 Carbon dioxide
CTNF Corrected total neurofilament fluorescence
DIV Days in vitro
E2 Estradiol
ER Estrogen receptor
LTP Long-term potentiation
NF-68 Neurofilament 68 kD
PBS Phosphate-buffered saline
RA All-trans retinoic acid
RB All-trans retinoic acid with BDNF
RC All-trans retinoic acid with CHOL
RCB All-trans retinoic acid with CHOL and BDNF
RCBE All-trans retinoic acid with CHOL, BDNF and E2
RE All-trans retinoic acid with E2
RT Room temperature
TrkB Tropomyosin-related kinase B
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Introduction
Neuroblastoma is the most common extra-cranial solid
malignant tumor of sympathetic nervous system in infants
and young children [1]. Regardless of its stage, until today,
there is no cure or treatment, which could offer good
prognosis for patients [2, 3]. Human SH-SY5Y cell line,
used in this study, is a subclone of SK-N-SH cell line
which was isolated from a bone marrow of a 4 year-old
female patient [4]. SH-SY5Y cells maintain their potential
for regression, which results in aggressive proliferation of
these cells [5]. Novel therapeutic treatments inducing dif-
ferentiation into neuronal cell types could help to improve
the prognosis of children suffering from neuroblastoma [6].
The induction of differentiation could serve as a strategy to
inhibit cell population growth and eventually stop the
tumor growth, as well as induce healthy mature neurons in
patients.
Previous studies have presented that differentiation of
SH-SY5Y cells can be induced by dibutyryl cyclic AMP
[5, 7], 12-o-tetradecanoyl-phorbol-13-acetate [8–13], all-
trans-retinoic-acid (RA) [9, 14–16], brain-derived neu-
rotrophic factor (BDNF) [17–19], vanadate [20], nerve
growth factor [21, 22], cholesterol (CHOL) [23], vitamin
D3, and neuregulin beta1 [24]. The signaling pathways that
lead to terminal differentiation of SH-SY5Y cells, how-
ever, are still largely unknown.
The retinoic acid (RA) is a potent cell differentiating
factor, which through its nuclear receptors affects a vast
range of promoter sites in the neuronal and glial cells in
every step of embryonic and postnatal life [25]. RA-in-
duced differentiation has been shown to inhibit cell pro-
liferation [9], change cellular sodium conductance [15],
enhance the outgrowth of neurites [16], increase the
acetylcholinesterase (AChE) activity [26, 27], and enhance
the synaptic vesicle recycling [23]. However, clinical trials
have demonstrated that treatment with RA alone, or in
combination with interferon alpha, is not enough against
recurrent neuroblastoma in children [28, 29]. Therefore,
new alternative resources for more effective neuronal dif-
ferentiation are needed.
Cholesterol (CHOL) is a necessary component in cell
membranes and important for synaptic structure and
function [30]. It is synthesized by neurons themselves for
their survival and growth. The development of active
synapses requires additional amount of cholesterol that is
shown to be secreted by glial cells (specifically astrocytes)
in the central nervous system [30–32] and by Schwann
cells in the peripheral nervous system [33]. The glia-
derived cholesterol has also been shown to be crucial for
differentiation of dendrites, synaptogenesis, increase in
synaptic protein expression (synapsin-1) and neuronal
activity, and for transmitter release [30, 32, 34, 35]. In pure
human SH-SY5Y cell cultures, the glia-derived cholesterol
is non-existing, and addition of cholesterol is needed in
order to achieve conditions resembling normal neuronal
environment with surrounding glial cells [23].
The brain-derived neurotrophic factor (BDNF) has been
shown to support the survival of neurons and stimulate the
growth and differentiation of new neurons and synapses
[36]. BDNF is a ligand for tropomyosin-related kinase B
(TrkB) receptor, expression of which is lacking in naı¨ve
neuroblastoma cells. However, TrkB receptor expression
and responsiveness to BDNF is induced by RA [37]. The
activation of TrkB by BDNF has been suggested to
enhance neuroblastoma cell survival and resistance to
chemotherapy [38]. BDNF has also been shown to expose
only a modest benefit for RA-induced arrest in a dormant
state [6]. However, the sequential treatment of SH-SY5Y
cells with RA and BDNF has been reported to induce
differentiated, neurotrophic factor-dependent neuron-like
cells [18] and sustained treatment has been reported to
enhance neuronal differentiation of neural progenitor cells
[39]. Moreover, RA-BDNF treatment induces significant
increase in the expression of synaptic genes, brain miRNA,
miRNA biogenesis machinery, and AChE activity, in
comparison to sole RA treatment [19]. These studies
stimulate the interest to further examine the potential
therapeutic competence of BDNF for RA-induced SH-
SY5Y cell differentiation and for treatment of neuroblas-
toma. Disruption of BDNF and its downstream signaling
pathways have been observed in many neurodegenerative
diseases such as Alzheimer’s, Parkinson’s and Hunting-
ton’s diseases [40–42], underlining the importance of
BDNF. However, the results of the role of added exoge-
nous BDNF for differentiation of RA treated SH-SY5Y
cells are still controversial.
Estradiol (17-beta-estradiol, E2), a form of estrogen
hormone, has both acute and long-term effects on a variety
of neuronal cell types. Increase in the number of dendritic
spines and number of excitatory synapses, which are the
slow long-term effects of estradiol, were first detected [43–
45]. The acute effects, which alter the intrinsic and synaptic
physiology of neurons within minutes (reversible depolar-
ization and increased input resistance with a latency of
\1 min in 19.8 % of CA1 neurons tested) were detected
later [46, 47]. Several studies have shown that estrogen
enhances synaptogenesis and synaptic plasticity [48–55],
which properties may be crucial for example in enhancing
memory consolidation [43, 56]. Additionally, estrogen has
been demonstrated to induce synaptic connectivity [52],
enhance NMDA receptor expression and activity [57–66],
and long-term potentiation (LTP) [58, 59, 64, 67].
Several earlier studies have addressed possible signaling
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mechanisms associated with estrogen-induced cellular
functions. Estrogen activates these functions through the
activation of estrogen receptors (ERs), ERa and ERb,
which serve as transcription factors modifying the activity
of target genes [68, 69]. Estrogen has been shown to
increase the key synaptic proteins, e.g. PSD-95, via either
activation of ERa [70], ERb [51], or both [71]. Estrogen is
thought to use both nuclear ERs and plasma membrane
ERs which are usually referred to as classical genomic and
non-genomic pathways [69]. In classical genomic action,
ERs are thought to translocate into nucleus in ligand-de-
pendent manner and acting as a transcription factor of
target genes after prolonged estrogen exposure [72]. In
non-genomic action, estrogen has been shown to activate
the membrane ERs, which rapidly stimulate the membrane-
associated signaling molecules such as PI-3K and MAPK,
resulting in quick increase in protein expression [73, 74].
SH-SY5Y cells have been shown to express both ERa and
ERb [75]. Estrogen has also been shown to stimulate the
activity-regulated cytoskeleton associated protein (Arc)
expression via the MAPK and PI-3K dependent pathway in
SH-SY5Y cells [48]. Arc is known to be induced by neu-
ronal activity and playing a key role in activity-dependent
synaptic plasticity [76]. Its knockdown has been shown to
lead to impairment of long-term memory [77, 78]. How-
ever, the specific role of E2 for inducing differentiation in
human SH-SY5Y neuroblastoma cells is still unknown.
The main goal of the current study was to find a func-
tional combination of substances for effective induction of
differentiation of the SH-SY5Y cells. Based on our earlier
studies, we used RA and CHOL as primary differentiation
treatments [23]. We further investigated the ability of E2
and BDNF to support, and possible enhance, the RA and
CHOL induced neuronal differentiation. We quantified the
individual and additive impacts of BDNF and E2 on the RA
and CHOL-induced neurite outgrowth, presence of neuro-
filament 68, synaptic vesicle recycling and arrest in the
population growth rate of SH-SY5Y neuroblastoma cells
in vitro.
Methods
Maintenance and Differentiation of Cell Cultures
The human SH-SY5Y neuroblastoma cell line (CRL-2266;
American Type Culture Collection, Manassas, VA, USA)
was cultured as previously described [23]. Briefly, the cells
were plated at passage 29–30 with density of 5000 cells/
cm2 on 48-well culture dishes. Cells were cultured and
maintained in 5 % CO2 humidified incubator at 37 C in
1:1 nutrient mixture F-12K Kaighn’s modification, and
minimum essential medium supplemented with 10 % fetal
bovine serum, 2 mM/L L-glutamine, 1 % antibiotic–an-
timycotic mixture and 1 % non-essential amino acids (all
reagents from GIBCO, Invitrogen, Carlsbad, CA, USA,
unless otherwise stated). Cell differentiation was induced
with 10 lM/L all-trans retinoid-acid (RA), 1 nM/L
17-beta-estradiol (E2), 50 ng/mL brain-derived neu-
rotrophic factor (BDNF), 10 lg/mL cholesterol (3b-hy-
droxy-5-cholestene, CHOL), or with combinations such as
(i) 5 lM/L RA with 5 lg/mL CHOL (RC), (ii) 5 lM/L RA
with 50 ng/mL BDNF (RB), (iii) 5 lM/L RA with 1 nM/L
E2 (RE), (iv) 5 lM/L RA with 5 lg/mL CHOL, and 50 ng/
mL BDNF (RCB), and (v) 5 lM/L RA with 5 lg/mL
CHOL, 50 ng/mL BDNF, and 1 nM/L E2 (RCBE) for 10
DIV (all differentiation reagents from Sigma-Aldrich, St
Louis, MO, USA, unless otherwise stated). Stock solutions
of differentiation substances were diluted in 96 % ethanol;
the final ethanol concentration never exceeded 0.1 % in
cell culture. Control cells were treated with\0.1 % etha-
nol. All used substance concentrations were carefully
evaluated according to already published literature. Sui-
table, least toxic concentrations, also used by other labo-
ratories, were used to enable comparison of our results with
others. All differentiation substances (except BDNF when
used in combinations) were applied with medium exchange
at 1, 3 and 7 DIV. BDNF was applied at 4 and 7 DIV when
used together with RA (RB), RA and CHOL (RCB) or RA,
CHOL and E2 (RCBE). The cell growth, condition, and
morphology were observed with culture microscope
(Olympus CK40) and images were taken at 10 DIV DP10
microscope digital camera system (Olympus, Tokyo,
Japan).
Neurofilament Staining
For detecting the level of differentiation in the neuroblas-
toma cell cultures, the cells were stained at 10 DIV with
neuronal marker NF-68 for neurofilament light polypeptide
(68 kDa, Sigma-Aldrich). Cells were first fixed for 20 min
with 4 % paraformaldehyde (Sigma-Aldrich) in phosphate
buffered saline solution (PBS), washed three times with
PBS and permeabilized in 0.5 % Triton X-100 (J.T. Baker,
Phillipsburg, NJ, USA) for 15 min. After washing with
PBS, the non-specific antibody binding sites were blocked
with 10 % bovine serum albumin (GIBCO) in PBS for
30 min to reduce the background. Cells were then incu-
bated with the primary antibody mouse monoclonal anti-
NF-68 1:200 for 1 h at room temperature (RT; ?22 C),
rinsed three times with PBS, and then incubated with a
secondary antibody FITC-conjugated goat anti-mouse IgG
1:100 (Sigma-Aldrich) for 30 min at RT. Fluorescence was
visualized with Nikon Eclipse TS100 microscope equipped
with Nikon DS Camera Control Unit DS L-1 and images
were organized with Visio 2010 (Microsoft, WA, USA).
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The intensity of total neurofilament fluorescence (NF-68)
and the intensity of total background fluorescence were
measured from each fluorescence image with ImageJ
software (National Institute of Mental Health, Bethesda,
Maryland, USA) [79]. Corrected total neurofilament fluo-
rescence (CTNF) was calculated from the gathered data in
Excel 2010 (Microsoft, WA, USA) with the method used
previously [80, 81], as follows: The fluorescence of the
neurofilaments of interest was selected using the selection
tool. Area of interest, integrated density, and mean gray
value were calculated from selected areas with ImageJ
software. A region next to the selected neurofilament was
selected as a background value. The CTNF was calculated
by using the following equation CTNF = integrated den-
sity - (area of selected neurofilaments 9 mean fluores-
cence of background readings).
Quantification of Cell Population Growth
The substance-induced changes in the growth rate were
quantified by counting the nuclei of 10 DIV cultured SH-
SY5Y cells in each treatment group. Cell nuclei were
stained with 10 lg/mL Hoechst 33258 (Sigma-Aldrich) for
5 min. Cultures were washed five times in PBS and
mounted on cover slips. Fluorescence results were visual-
ized with Nikon DS Camera Control Unit DS L-1. Images
of each treatment group were analyzed with CellC analysis
software [82], which corrects the image background for
auto-fluorescence by fitting a two-dimensional quadratic
polynomial to the image and subtracts the fitted polynomial
surface from the original image. After this the algorithm
separates the nuclei pixels from background pixels by
global thresholding and produces a binarized image with
white nuclei on a black background. It furthermore sepa-
rates clustered nuclei from each other by marker-controlled
watershed segmentation, which is based on nuclei inten-
sity. Eventually the software removes artifacts, such as
staining residues by discarding objects smaller than 1/10 of
the mean size of all objects. Images were organized with
Microsoft Visio 2010. The obtained nuclei counts and
statistics (see section ‘‘Statistical Analysis’’) were analyzed
and plotted in MATLAB (version 2013b, The Mathworks
Inc., MA, USA).
Quantification of Neurite Length
The SH-SY5Y cells were cultured in CTRL, CHOL, E2,
BDNF, RA, RE, RB, RC and RCBE conditions at 10 DIV.
Neurites were traced from phase contrast images of each
treatment group with NeuronGrowth plugin [83] of the
ImageJ software (National Institute of Mental Health,
Bethesda, Maryland, USA) [79]. The NeuronGrowth
automatically counts the length of traced neurites in pixels
and exports the data. The gathered data and statistics were
analyzed and plotted in MATLAB (version 2013b, The
Mathworks Inc., MA, USA).
Synaptic Vesicle Recycling
The level of synaptic vesicle recycling was verified by
measuring the number of fluorescence puncta in 10 DIV
cultured SH-SY5Y cells. Cells were treated either with
\0.1 % ethanol (CTRL), RA, CHOL, BDNF, E2, or with
their combinations. Cultures were stained with AM1-43
styryl dye (Biotium, Hayward, CA, USA) for detecting
synaptic exo/endocytosis in cells. AM1-43 is a fixable
nerve terminal probe. It is not able to pass through the
membranes, but instead, when cells are depolarized with
high potassium (K?)-Tyrode solution, AM1-43 styryl dye
attaches inside those vesicles, which are ongoing exocy-
tosis. Staining was modified from method previously
described [23, 84, 85]. In the current experiments, the cells
were incubated for 1 min with 4 lmol/L AM1-43,
according to manufacturer’s protocol, with the depolarizing
Tyrode solution including 80 mmol/L K? (80 mmol/L
KCl, 29 mmol/L NaCl, 2 mmol/L MgCl2, 30 mmol/L
glucose, 25 mmol/L HEPES, 2 mmol/L CaCl2). Cells were
further washed several times with SCAS quencher solution
(Biotium, Hayward, CA, USA) at RT to reduce background
fluorescence. Cells were fixed for 20 min with 4 %
paraformaldehyde (GIBCO), permeabilized in 0.01 %
Triton X-100 (J.T. Baker) for 12 min and washed three
times for 1 min in cold PBS. All reagents were from Sigma
Aldrich unless otherwise stated. The fluorescence was
visualized with Nikon Eclipse TS100 microscope equipped
with Nikon DS Camera Control Unit DS L-1 and images
were organized with Microsoft Visio 2010. Fluorescence
images of each treatment group were analyzed with ImageJ
analysis software [79] using the following procedural steps
specifically designed to this study: background of the
image was subtracted by setting a rolling ball radius to 50
pixels, after image was sharpened, and then the maxima of
fluorescence puncta were found with noise tolerance of 20
and with the point selection style. This procedure was
evaluated by visual inspection and it was found to be the
best for finding the correct number of AM1-43 puncta from
fluorescence images. The obtained counts of fluorescence
puncta per image were divided by the obtained median
nuclei number (see section ‘‘Quantification of Cell Popu-
lation Growth’’) in particular culture in 10 DIV treatments.
These obtained counts of fluorescence puncta per median
nuclei number and statistics (see section ‘‘Statistical
Analysis’’) were analyzed and plotted in MATLAB (ver-
sion 2013b).
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Summary of the Level of Differentiation
Results are summarized in Table 1, which shows the level
of differentiation induced by different treatments. The level
of differentiation was assessed at least from three samples
from two separate experiments by analyzing the following
features; neurite length, presence of neurofilaments, inhi-
bition in cell population growth rate and synaptic vesicle
recycling. Neurite lengths were detected both visually and,
by using automated methods to support the visual detec-
tion. Other features were defined according to the methods
explained above (see sections ‘‘Neurofilament Staining,
Quantification of Cell Population Growth and Synaptic
Vesicle Recycling’’).
Statistical Analysis
Statistical analysis was performed using One-way ANOVA
in MATLAB (version 2013b). Differences were considered
to be significant when p\ 0.01 or p\ 0.05, different
significances are indicated with ** or * in the figures,
respectively.
Results
Morphology of Differentiated SH-SY5Y Cells
Phase contrast images of SH-SY5Y cultures at 10 DIV
were first visually analyzed for morphological assessment.
In the visual analysis, control cells showed no particular
neurite outgrowth (Fig. 1a), whereas CHOL-treated cells
had a number of short neurites (green arrows in Fig. 1b; see
also Table 1). Cells treated with E2 had very short neurites
(Fig. 1c), which were both fewer and shorter than the
CHOL-induced neurites. The morphology of BDNF treated
SH-SY5Y was relatively polar and cells grew more spread
in the culture dish (Fig. 1d). This differed from control
cells, which grew in clusters (Fig. 1a). No significant out-
growth of neurites was observed after BDNF treatment.
Treatment with RA alone (Fig. 1e) as well as with com-
binations such as RE, RB, RC, RCB or RCBE, induced
branching of longer neurites and detectable network for-
mation (Fig. 1f–j, respectively).
The data show other morphological differences between
the treatments as well. The RE treated SH-SY5Y cells had
Table 1 Summary of differentiation
Treatment Neurite length Total neurofilament fluorescence Inhibition of cell population growth Synaptic vesicle recycling
CTRL - - - -
CHOL ??** - - -
E2 ?* - - ?*
BDNF - - - -
RA ???** ???** ???** ??**
RE ???** ??* ???** ??**
RC ???** ???** ???** ???*
RB ???** ???** ?? ??**
RCB ???**   ???*
RCBE ???** ???**  ???*
The criteria for categorizing the neurite length were as follows: - neurites similar to control, ? short neurites without branching and signifi-
cantly longer than in control [p\ 0.05 (*)], ?? intermediate neurites without branching and significantly longer than in control [p\ 0.01 (**)],
??? long neurites with branching and significantly longer than in control [p\ 0.01 (**)] and in CHOL or E2 treatment conditions [p\ 0.01
(**)]. The criteria for categorizing the total neurofilament fluorescence were as follows: - no neurofilament fluorescence, ?? significantly
[p\ 0.05 (*)] increased neurofilament fluorescence compared to control, ??? significantly [p\ 0.01 (**)] increased neurofilament fluores-
cence compared to control. The criteria for categorizing the inhibition of cell population growth were as follows: - the number of cells has not
changed after the treatment, ?? the number of cells decreased (not significantly), ??? the number of cells significantly [p\ 0.01 (**)]
decreased. The criteria for categorizing the amount of synaptic vesicle recycling were as follows: - no significant change in the counts of puncta
in comparison to control, ? significant [p\ 0.05 (*)] increase in the counts of fluorescence puncta in comparison to control, ?? significant
[p\ 0.01 (**)] increase in the counts of fluorescence puncta in comparison to control, ??? significant [p\ 0.05 (*)] increase in the counts of
fluorescence puncta in comparison to RE and RB
 Control (CTRL,\0.1 % ethanol), cholesterol (CHOL; 10 lg/ml), 17-beta-estradiol (E2; 1 nM/L), brain derived neurotrophic factor (BDNF;
50 ng/mL), all-trans retinoic acid (RA; 10 lg/mL), RA with E2 (RE; RA 5 lg/mL, E2 1 nM/L), RA with CHOL (RC; RA 5 lg/mL, CHOL 5 lg/
mL), RA with BDNF (RB; RA 5 lg/mL, BDNF 50 ng/mL), RA with CHOL and BDNF (RCB; RA 5 lg/mL, CHOL 5 lg/mL, BDNF 50 ng/
mL), RA with CHOL, BDNF and E2 (RCBE; RA 5 lg/mL, CHOL 5 lg/mL, BDNF 50 ng/mL, E2 1 nM/L)
 Conclusive data not available
Neurochem Res (2016) 41:731–747 735
123
Fig. 1 Morphology and
network formation of SH-SY5Y
neuroblastoma cells at 10 DIV.
a SH-SY5Y cells were grown
for 10 DIV in control conditions
(CTRL) and with b cholesterol
(CHOL), c estradiol (E2),
d brain-derived neurotrophic
factor (BDNF), e all-trans
retinoic-acid (RA), or with their
combinations f–j RE, RB, RC,
RCB, RCBE, respectively. Data
show that the CHOL treatment
induced short neurites (green
arrows) with many varicosities
(red arrows) (b). E2 induced
few very short neurites in
comparison to CHOL induced
neurites (c). BDNF treatment
did not induce significant
growth of neurites or network
formation (d). RA treatment
generated thin branching
neurites and promoted network
formation (blue arrows, e).
Networks of cells with cell-to
cell contacts (blue arrows) were
always detected when treated
with RA together with f E2
(RE), g BDNF (RB), h CHOL
(RC), i CHOL and BDNF
(RCB), and j CHOL, BDNF,
and E2 (RCBE). Flat substrate-
adherent (S-type) cells were
detected especially when cells
were treated with E2 or BDNF
(orange arrows) (c, d) but also
when cells were treated with RE
(data not shown) or RB (orange
arrows) (g). The RE treated
cells (f) had thinner neurites
than those treated with RCBE
(j) (Color figure online)
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networks of roundish cells with thin neurites without heavy
branching (Fig. 1f). A small number of substrate-adherent
(S-type) flat cells [86] were observed in cultures treated
with RE (data not shown), RB (orange arrows in Fig. 1g)
and RA (data not shown). The RB treatment induced net-
works that consisted of extended contacting neurites, as
well as of cells in direct contact with each other without
neurites. The neurites of the RB treated cells were thicker
in comparison to RE induced neurites. The RC treatment
induced cells with long, branching and connecting neurites
(blue arrows in Fig. 1h). Other cholesterol treated cultures,
such as RCB and RCBE, contained neurons with long
branching neurites and network formation without S-type
cells. More varicosities (red arrows in Fig. 1b) and small
cell clusters (data not shown) were observed in CHOL
treated cultures (CHOL, RC, RCB, RCBE) in comparison
to the control, RE and RB treated groups, in which cells
were more uniformly distributed (data not shown).
Inhibition of Cell Population Growth
The ability of a substance to inhibit the population growth
of human SH-SY5Y cells is one of the indicators of
increased level of differentiation. Therefore, we counted
the numbers of the Hoechst 33258 stained nuclei at 10 DIV
in RA, CHOL, BDNF, E2, RE, RB, and RC treated cell
cultures and compared the results to the number of nuclei
in control conditions. The data demonstrated that CHOL,
E2 or BDNF treatments on their own did not inhibit the cell
population growth (Fig. 2), which, however, was seen
when treated with RA, as well as with RA together with
CHOL (RC) [p\ 0.01(**)] when compared to controls.
Moreover, significant (p\ 0.01 (**) inhibition was also
detected with RA together with E2 (RE) treatment, when
compared to controls (Fig. 2). Interestingly, when cells
were treated with RA and BDNF, no inhibition of growth
was detected (Fig. 2).
Neurite Lengths
The neurites of SH-SY5Y cells were traced from phase
contrast images taken from each experiment at 10 DIV
with NeuronGrowth (see section ‘‘Methods’’), which pro-
vides supportive information of the lengths in addition to
the visual inspection of the cell morphology. In addition to
RA [p\ 0.01 (**)], also with CHOL alone [p\ 0.01 (**)]
and E2 alone [p\ 0.05 (*)] treatments, induced a signifi-
cant increase in the length of neurites in comparison to
control cells at 10 DIV (Fig. 3). Furthermore, the signifi-
cant increase in the neurite length was seen in all
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Fig. 2 Inhibition of cell population growth. Cells were cultured in
control conditions [CTRL (n = 7)], and with CHOL (n = 6), E2
(n = 6), BDNF (n = 6), RA (n = 6), RE (n = 6), RB (n = 6), and
RC (n = 8) (n is the number of analyzed microscopy images) and
the cell nuclei were counted at 10 DIV. In the boxplot representation
the obtained median nuclei counts, 25th and 75th percentiles,
extreme data points, and outliers of the data are shown with red
line, blue edges, black whiskers, and red asterisks, respectively.
Each differentiation agent is shown on the x-axis and the cell nuclei
counts on the y-axis. The statistically significant differences
(p\ 0.01) are shown with asterisks (**). Significantly lower cell
numbers were detected when cells were treated with RA, RE, or RC
in comparison to CTRL data. Slight increase in cell numbers (nuclei
counts) were observed when cells were treated with RB, in
comparison to the cells treated solely with RA. The nuclei counts
of RB treated cultures were not significantly lower in comparison to
CTRL (Color figure online)
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combination treatments such as RE, RB, RC, RCBE
[p\ 0.01 (**)] relative to control conditions (Fig. 3). With
the BDNF treatment alone no increase in the neurite length
was detected.
Presence of Neurofilaments in SH-SY5Y
Neuroblastoma Cells
The level of differentiation of the SH-SY5Y neuroblastoma
cells at 10 DIV was further verified by imaging the NF-68
neurofilaments. The neurofilament fluorescence was
defined by visual inspection and by measuring the intensity
of CTNF, when cells were treated solely with RA, BDNF,
CHOL, or E2 (Fig. 4b–e, respectively) or in combination
with RA and E2 (RE), RA and BDNF (RB), RA and CHOL
(RC), and RA, CHOL, BDNF, and E2 (RCBE) (Fig. 4g–j,
respectively). Both visual and automated image analyses
showed that the presence of the NF-68 neurofilaments was
clearly induced by RA (Fig. 4b). No major increase in NF-
68 fluorescence levels was observed visually or automati-
cally, when cells were treated with BDNF, CHOL or E2
(Fig. 4c–e). However, the intensity of NF-68 fluorescence
was significantly increased in all of the combination
treatments relative to control cells, as shown in Fig. 4g–j,
and in Fig. 5 for RA [p\ 0.01 (**)], RE [p\ 0.05(*)],
RC [p\ 0.01(**)], RB [p\ 0.01(**)] and RCBE
[p\ 0.01(**)].
Differentiation-Induced Synaptic Vesicle Recycling
Our group has earlier shown that RA and RC treated
human SH-SY5Y cells show intense Synaptophysin I
(SypI) fluorescence in cell somata, along the neurites and at
the sites of the cell-to-cell contacts. Furthermore, we have
shown co-localization of SypI and AM1-43 at the end of
the neurites at the cell-to-cell contacts of the RA and RC
differentiated and high K? depolarized human SH-SY5Y
cells [23]. It has been also shown elsewhere that the SH-
SY5Y cells are capable of depolarization with high K?
stimulation [87]. Therefore, high K? stimulation was used
for studying the stimulation-related synaptic vesicle recy-
cling also in this study. The SH-SY5Y neuroblastoma cells
were incubated with E2, CHOL, BDNF, or RA or with their
combinations (RE, RB, RC, RCB and RCBE) and stained
at 10 DIV with AM1-43, a fluorescent styryl dye (a nerve
terminal probe) with the presence of depolarizing high K?-
Tyrode solution. The number of fluorescent puncta,
reflecting the recycling synaptic vesicles, was counted after
depolarization (see Fig. 6 and section ‘‘Methods’’). Treat-
ment with CHOL or BDNF alone does not increase the
number of fluorescence puncta in comparison to CTRL.
Our data show for the first time, that the treatment with E2
alone [p\ 0.05(*)], or RA together with E2 (RE), BDNF
(RB), BDNF and CHOL (RBC) or BDNF, CHOL and E2
(RBCE), [p\ 0.01(**)] significantly increases the number
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Fig. 3 Neurite lengths in SH-SY5Y cells. Cells were cultured in
CTRL conditions, and with CHOL, E2, BDNF, RA, or with their
combinations; RE, RB, RC, RCBE. In the boxplot representation the
obtained median of neurite lengths, the 25th and 75th percentiles, the
extreme data points, and the outliers of the data are shown with red
line, blue edges, black whiskers and red asterisks, respectively. Each
treatment is shown on x-axis and the neurite lengths in pixels on
y-axis. The statistically significant differences (p\ 0.01) and
(p\ 0.05) are shown with asterisks (**) and (*), respectively. The
neurite lengths were significantly longer when cells are treated with
RA, CHOL, RE, RB, RC, and RCBE (p\ 0.01). Interestingly, at 10
DIV, E2 induces only short neurites, but the increase in the neurite
length is still significant in comparison to controls (p\ 0.05).
Moreover, RA induces significantly longer neurites when compared
to CHOL or E2 induced neurite lengths (p\ 0.01) (Color
figure online)
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Fig. 4 The presence of NF-68
neurofilaments in SH-SY5Y
neuroblastoma cells.
Neurofilaments were detected at
10 DIV by immunostaining of
NF-68 (green) and cell nuclei
with Hoechst 33258 (blue). a–
e Combined double staining of
neurofilaments and nuclei in the
SH-SY5Y cells in control
conditions (CTRL), and when
treated with RA, BDNF, CHOL
and E2, show that RA induces
NF-68, seen also in the long
branching neurites. a, f No NF-
68 is seen in CTRL. g–j RE,
RB, RC and RCBE treatments
show presence of
neurofilaments similar to those
with RA alone (Color
figure online)
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of fluorescence puncta when compared to controls. The
results also confirm earlier results from our laboratory that
RA alone, as well as together with CHOL, significantly
[p\ 0.01(**)] increases the number of AM1-43 fluores-
cence puncta in SH-SY5Y cells. This data also indicate a
slight, however not significant, increase in fluorescence
puncta in CHOL treated cultures, but not in BDNF treated
cultures. In particular, we found a significant [p\ 0.05(*)]
increase in cells treated with RCB or RCBE relative to
cultures treated without CHOL (such as RB or RE). These
results demonstrate that in addition to RA and CHOL, also
prolonged treatment with E2 alone stimulates the synaptic
vesicle recycling in SH-SY5Y cells. Highest numbers of
fluorescence puncta were detected when all agents were
combined (RCBE).
Discussion
Despite active research for improving the prognosis of
high-risk neuroblastoma patients over the last decades,
only a few patients become long-term survivors. Outcome
of the stage 4 neuroblastoma remains poor, and the
development of novel therapeutic approaches is needed
[28, 88–91]. Therefore, therapies such as induced
differentiation of cancer cells are important. Retinoic acid
is one of the most prominent inducer of differentiation in
clinical treatments [28, 90]. Therefore, in the current study,
the level of differentiation of human SH-SY5Y cells
towards neuronal type was followed by analyzing the
additive impacts of estradiol (E2/E) and brain-derived
neurotrophic factor (BDNF/B) on cell morphology, neurite
length, presence of neurofilaments, cell population growth
and synaptic vesicle recycling in non-treated controls, as
well as retinoic acid (RA/R) and cholesterol (CHOL/C)
treated cells at 10 days in vitro.
We here confirm our earlier data [23] that the most
potent inducer for differentiation is retinoic acid, especially
with co-treatment with CHOL. Of the four markers of
differentiation (cell population growth, neurite length, total
NF-68 fluorescence and synaptic vesicle recycling) growth
is inhibited only when RA is present. Estradiol (E2), a
predominant form of estrogen hormone, as well as CHOL,
supports this inhibition. Growth rate of the cells treated
with RA together with BDNF (RB) was higher than those,
which were treated with RA alone. BDNF thus opposes the
possibility of cells to undergo RA induced growth inhibi-
tion. Earlier results by other laboratories of the impact of
BDNF, and in particular of the treatment together with RA,
have given controversial results. While some studies show
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Fig. 5 Corrected total NF-68 neurofilament fluorescence (CTNF).
CTNF was analyzed from the control (CTRL) SH-SY5Y cells
(n = 19), and cells treated with RA (n = 38), BDNF (n = 6), CHOL
(n = 6) and E2 (n = 6) and RC (n = 9), RB (n = 14), RE (n = 13)
and RCBE (n = 13) (n is the number of analyzed images). The
obtained median of CTNF, the 25th and 75th percentiles, the extreme
data points, and the outliers of the data are shown in the boxplot with
red line, blue edges, black whiskers and red asterisks, respectively.
Differentiation agents are shown on the x-axis and the CTNF on the
y-axis. The statistical differences between the CTNF data and control
values are shown with asterisks [p\ 0.05(*), and p\ 0.01(**)]. The
automated analysis confirmed that the CTNF was significantly
[p\ 0.01(**)] increased in all other RA treated cultures (RA, RB,
RC, RCB, and RCBE) in comparison to control cultures, except
increased with less significance in the RE treated cultures
[p\ 0.05(*)]. This data show that NF-68 neurofilaments were
induced by RA and further maintained by CHOL, BDNF and E2
(Color figure online)
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that the RB treatment differentiated the SH-SY5Y cells
[18, 19, 37], other studies show that the activation of TrkB-
BDNF pathway, which is also activated by RB treatment,
can lead to increased cell survival, invasion, metastasis,
angiogenesis and drug resistance [92–96]. Our results of
population growth of RB treated cells are in agreement
with the study by Cernaianu et al. [6], showing that the
effect on proliferation depends on the used concentration of
BDNF, causing either significant inhibition (with 10 ng/
mL BDNF) or no inhibition (with 50 or 100 ng/mL) and
with the study by Nishida et al. [97], where they show that
SH-SY5Y-A cells (American Type Culture Collection; also
used in this study) differentiated in the presence of RA
whereas RA treated SH-SY5Y-E cells (European Collec-
tion of Cell Cultures) require additional BDNF treatment
for full differentiation. This is due to the defects in several
signaling pathways in SH-SY5Y-E cells. In conclusion, the
controversial results in the level of differentiation in some
of the studies might originate from the different subtypes of
SH-SY5Y, as well as from the used BDNF concentrations.
In the light of the current knowledge further examinations
of the properties of BDNF are needed, before considering
the use of BDNF as a therapeutic agent for clinical use.
Long neurites, typical of neuronal morphology, are
found with treatment by retinoic acid, as well as by
cholesterol. We here show, that E2 alone (at 1 nM con-
centration) is able to slightly increase the length of neu-
rites, and when it is combined with RA (RE) or
additionally with CHOL and BDNF (RCBE) neurites’
length is even more enhanced involving also branching and
network formation. It has been earlier demonstrated by
Takahashi et al. [98], that 10 nM E2 induces neurite out-
growth already after 2 DIV, which was not seen in this
study. This difference in the presence of neurites may be
explained by the 10 times difference in the E2 concentra-
tions used. With treatment by BDNF alone, no neurite
outgrowth at 10 DIV was detected. This result is under-
standable based on other reports that 3–5 days’ RA treat-
ment is necessary to induce expression of TrkB receptors,
which are crucial for BDNF induced neurite growth [18,
37]. Agholme et al. [24] have shown, that the RB and RCB
treatments induced longer neurites than treatment with RA
alone, which were not seen in our experiments. We addi-
tionally show, similarly to the results shown in previous
studies, that RA alone [16, 23, 99] or when combined with
CHOL (RC) [23], BDNF (RB) [100], or CHOL and BDNF
(RCB) [24] induce considerable neurite outgrowth and
neuronal networks.
Neurofilaments are major components of the neuronal
cytoskeleton, providing structural support for the axons and
regulating the axon’s diameter. We here show that treat-
ment with RA alone enhances the total light neurofilament
(NF-68) fluorescence. Earlier study from Messi et al. [101]
is in agreement with our results by showing that RA
reduces cell migration and invasiveness and up regulates
NF-68 expression. In addition, it has been shown that
medium size neurofilaments (NF-145-160) are induced by
RA in SH-SY5Y cells [102]. We detected that RA com-
bined to E2 enhanced the total NF-68 fluorescence, though
less than the RC, RB, RCB or RCBE treatments. The
enhancement of total NF-68 fluorescence in human SH-
SY5Y cells by these treatments has not been previously
reported.
Finally, we asked if RA, E2, CHOL and BDNF or their
combinations increase the synaptic vesicle recycling in SH-
SY5Y cells. Results from the current study are interesting,
as in addition to RA, also E2, even when used alone, is able
to significantly increase the number of detected vesicle
recycling after depolarizing cells by high K?-solution. Hu
et al. [103] have shown in cultured neonatal rat cortical
primary cells that E2, produced and secreted by astrocytes,
modulates synaptogenesis and synaptic function by
increasing the synaptic vesicle recycling. In addition, they
showed that added exogenic estradiol mimics this effect of
astrocyte-conditioned medium on synaptic formation and
transmission. Our results here are in agreement with this
study. Chamniansawat and Chongthammakun [48] have
shown that 48 h estrogen treatment significantly increases
the expression of synapse related proteins, such as post-
synaptic dense material 95 (PSD-95) and synaptophysin
(SYP). As they did not see any estrogen induced immediate
bFig. 6 Synaptic vesicle recycling in SH-SY5Y neuroblastoma cells.
a–j Synaptic vesicle recycling was measured by AM1-43 immunos-
taining in the presence of depolarizing high K? containing Tyrode
solution from control cells [CTRL (n = 12)] and cells treated with
CHOL (n = 6), E2 (n = 6), BDNF (n = 6), RA (n = 6), or with their
combinations such as RE (n = 6), RB (n = 6), RC (n = 6), RCB
(n = 6), or RCBE, (n = 9) at 10 DIV (n is the number of analyzed
images). ai–ji Magnified examples of every treatment are shown.
k Number of detected fluorescence puncta. In the boxplot, the
obtained median number of fluorescence puncta, the 25th and 75th
percentiles, the extreme data points, and the outliers of the data are
shown with red line, blue edges, black whiskers and red asterisks,
respectively. Differentiation agents are shown on the x-axis and the
number of AM1-43 fluorescence puncta per obtained median nuclei
number on the y-axis. The statistical differences between the data of
interest and control values are shown as asterisks [p\ 0.05(*), and
p\ 0.01(**)]. The number of fluorescence puncta did not signif-
icantly increase in comparison to CTRL group, when cells were
treated solely with CHOL or BDNF (b, d, k). E2 induced significant
increase [p\ 0.05(*)] in the number of AM1-43 puncta relative to
control group (c, k). The results show that RA alone, as well as RE,
RB, RC, RCB, and RCBE significantly [p\ 0.01(**)] increased the
number of AM1-43 puncta relative to control group (e–j). Addition-
ally, the synaptic vesicle recycling was significantly [p\ 0.05(*)]
increased when cholesterol was present (in RCB and RCBE treated
cultures) when compared to RB or RE treated groups without CHOL
(k). The highest median of number of fluorescence puncta was
detected when neuroblastoma cells were treated with all substances
simultaneously (RCBE) (Color figure online)
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or rapid effects on the PSD-95 and SYP mRNA expression
in SH-SY5Y cells, they concluded that the expressions of
PSD-95 and SYP requires translocalization across ER, as
well as long period of time to activate the target gene
expression in SH-SY5Y cells. This is called classical
genomic action of estrogen, where estrogen partially acts
through PI-3K signaling to activate PSD-95 and SYP
expression. Our data support the hypothesis that prolonged
treatment of E2 enhances endo/exocytosis and thus pro-
motes synaptic vesicle recycling in SH-SY5Y cells.
In the current study, synaptic vesicle recycling is sig-
nificantly enhanced in all combination treatments, where
cholesterol is present (RC, RCB and RCBE). Earlier it has
been shown that the depolarized RC treated cells induced
higher number of AM1-43 positive fluorescence puncta/
cell in comparison to depolarized RA treated cells [23]. We
now show for the first time that this same supra-additive
effect can be observed in addition to depolarized RC
treated cultures also in depolarized RCB and RCBE treated
cultures. Sarkanen et al. [23] found that one aspect possibly
explaining this effect of RA and CHOL is that the RA-
induced fragmentation of Golgi apparatus is avoided by co-
treatment with CHOL. In addition, it has been earlier
shown that RA has antioxidant potential and, that RA
isomers enhance the expression of genes linked with
cholesterol efflux e.g. apoe, abca-1 and abcg-1 proteins in
astrocytes [104]. We know also from other earlier studies
that synaptogenesis is promoted by cholesterol [30],
cholesterol influences multiple aspects of synaptic trans-
mission [105], both presynaptically, by acting on neuro-
transmitter vesicle fusion [106–108] and postsynaptically,
altering neurotransmitter receptor mobility in the mem-
brane [109]. Moreover, it is known that retinoic acid has
been shown to function in homeostatic plasticity as a sig-
naling molecule that increases synaptic strength by a pro-
tein synthesis-dependent mechanism [110]. It is also
known that homeostatic synaptic plasticity may manifest as
altered presynaptic transmitter release and vesicle loading
properties [111, 112]. All above mentioned studies support
our current result of the supra-additive effect of cholesterol
and retinoic acid on increasing the number of AM1-43
fluorescence puncta in SH-SY5Y cells when compared to
cells treated without CHOL.
Earlier and our results indicate that the formation of new
synapses is a complex process requiring the presence of
multiple substances simultaneously. Cholesterol is espe-
cially important as a component of cellular membranes,
regulating membrane structure, fluidity and permeability,
and as a precursor for steroid hormones. The increased
cholesterol efflux has been shown to impair the LTP at the
hippocampal CA1 synapses [34]. This study, together with
our results, indicates the importance of cholesterol in reg-
ulation of synaptic vesicle recycling, neurotransmission,
and regeneration of synapses. Lately, research has also
started to focus on the effects of estradiol (estrogen) on
formation and activity of synapses. A recent study on adult
male rat hippocampal slices shows that estradiol treatment
enhances synaptic transmission and LTP via estradiol
receptor beta (ERb) stimulation. Estradiol activates the
RhoA-GTPase signaling, which causes actin polymeriza-
tion within dendritic spines. The study suggests that
estradiol is able to increase the fast excitatory postsynaptic
potentials and causes a reduction in the threshold for last-
ing synaptic changes. Results of the study further indicate
that the estradiol (similarly to RA) activates the synaptic
TrkB receptors needed for the effects of the BDNF [113].
It is important to review the capacity of neuroblastoma
cells to differentiate into a neuronal cell type and link this
differentiation to those factors, which are normally pre-
sent in neuronal microenvironment. Amongst the various
glial cells in central nervous system, astrocytes are known
to release cholesterol and growth factors and thus promote
different aspects of synapse development [30]. Neurons
depend on import of cholesterol via lipoproteins [35] to
effectively maintain development of new connections via
dendrites, dendritic spines and synapses. The efficacy and
stability of the pre-synaptic transmitter release largely
depends on presence of cholesterol [32]. It is also known
that neurons are able to convert glia-derived cholesterol to
steroids, which then promotes synapse formation [114],
and that astrocytes, in addition to cholesterol also produce
and release estradiol, which enhances neurite growth
[115] and increases synapse number and function [103,
116]. In this study, we investigated whether cholesterol or
estradiol are able to increase synaptic vesicle recycling in
human SH-SY5Y cells, and it was found that estradiol,
even alone, is able to promote synaptic vesicle recycling
in these cells. Cholesterol, in contrast, does that only
when used together with retinoic acid. Our results indicate
the importance of estradiol, cholesterol and retinoic acid
in synaptic function.
The findings reported here have significance for under-
standing the effects of retinoic acid, cholesterol, estradiol
and brain derived neurotrophic factor, either alone or in
combinations in the process of SH-SY5Y neuroblastoma
cell differentiation into neuronal cell type. More than one
agent is clearly necessary to reach this goal in aim to
benefit the differentiation induced therapies.
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